Galectin Therapeutics Inc. (GALT) vs MacroGenics, Inc. (MGNX)

A side-by-side comparison of Galectin Therapeutics Inc. and MacroGenics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — GALT vs MGNX

growth of $100 · dividends reinvested · last 10y
GALT +166.4% (+10.3%/yr)MGNX -87.5% (-18.7%/yr)GALT compounded faster over this window
Log scale — wide-divergence pair
1101001kStart $10020182020202220242026$266$13
GALT MGNX

GALT vs MGNX: by the numbers

  • •GALT is the larger company ($238M vs $229M market cap).
  • •Both run net losses; GALT's is the smaller (0.00% vs -8.70% net margin).

Metrics side by side

Valuation

MetricGALTMGNX
P/S ratioN/A1.37
P/B ratioN/A5.34

Profitability

MetricGALTMGNX
Gross margin0.00%71.12%
Operating margin0.00%-48.72%
Net margin0.00%-8.70%
ROEN/A-34.04%
ROIC-1718.59%-16.87%

Growth (annualized)

MetricGALTMGNX
Revenue CAGR (5Y)N/A7.33%
Total return CAGR (5Y)0.60%-28.42%

Frequently asked

How have GALT and MGNX total returns compared?
Over the past 10 years, GALT delivered 13.41% and MGNX delivered -18.75% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.